Alecensa® (alectinib): Guidance for management of severe hypertriglyceridaemia

A Dear Healthcare Professional Letter has been issued by Roche Singapore Pte. Ltd. to inform healthcare professionals that hypertriglyceridaemia, including severe and life-threatening events, has been identified as a new risk with Alecensa^® (alectinib) based on cumulative data from clinical studies and postmarketing sources. Severe hypertriglyceridaemia is considered a medical emergency as it may lead to acute pancreatitis. Healthcare professionals are advised to obtain baseline blood triglyceride measurements from patients before starting Alecensa^® and periodically during treatment. Patients should be monitored for symptoms of acute pancreatitis, particularly those at increased risk. If severe or life-threatening triglyceride elevations occur, Alecensa® should be temporarily withheld until recovery to at least moderate hypertriglyceridaemia levels. Risk factors for pancreatitis should be evaluated, and treatable factors addressed before treatment initiation. Roche will be updating the product information to include this new risk and its associated recommendations. Please refer to the letter for details. Published: 16 Jan 2026

Dear Healthcare Professional Letters